Treatment of Khafaqan (Palpitation) with the Unani Medicine Jawarish-e-Tamar Hindi and Jawarish-e-Shahi

Comparative Clinical Validation study of Unani Pharmacopoeial Formulation Jawarish-e-Tamar Hindi vs Jawarish-e-Shahi in Khafaqan (Palpitation) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105563

Enrollment

318

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R002- Palpitations

Interventions

Intervention1: Jawarish e-Tamar Hindi: 05 gm twice daily, to be taken with plain water after meals for a duration of 4 weeks. Control Intervention1: Jawarish e- Shahi: 05 gm twice daily, to be taken w

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-65 years. 2. Patients experiencing palpitations who exhibit any of the following symptoms: I. Chest discomfort. II. Shortness of breath III. Missed Heart Beat Sensation. IV. Awareness of heart beating.

Exclusion criteria

Exclusion criteria: 1. Patients below 18 years and above 65 years of age. 2. Patients with history of structural heart disease. 3. Patients with cardiac pacemakers or other implanted electronic devices. 4. Any gross abnormality detected on ECG. 5. Patient with History of severe hepatic, renal/ respiratory disorder, diabetes mellitus, hypertension, hyperthyroidism, anemia. 6. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Improvement in the signs and symptoms of Khafaqan (palpitations). Which will be assessed on the basis of EQ 5D 5L questionnaire with EQ VAS.Timepoint: At baseline and subsequently at weekly intervals (i.e., Week 1, Week 2, Week 3, and Week 4) during the protocol therapy.	—

Secondary

Measure	Time frame
Haematological and biochemical investigations for safety assessment i.e., Hemogram, ESR, LFT, KFT, Urine Examination: Routine & MicroscopicTimepoint: At baseline, first Follow-up and at the end of the protocol therapy. i.e., 0, 1st & 4th week.	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

younismunshi@gmail.com09419086700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026